Good MorningA weaker than expected jobs report lifted the market. The contrarian logic is that weakening employment numbers will give the Federal Reserve room to pause its campaign of raising interest rates.
However, after a strong rally to start the day, stocks closed the week slightly lower. Higher bond yields have been pushing buyers away from stocks.
This week was a net win for the bears. And it sets the stage for economic data coming in next week. Palantir will deliver its quarterly earnings on Monday which is expected to be a market moving report. Investors will also get more information about the direction of inflation when the consumer price index (CPI) and producer price index (PPI) are released.
These reports could point to a continued downward trend. But investors should be cautious, because it’s likely that rising oil prices are not yet priced in.
Featured: Free SMS Stock Alerts from MarketBeat (Ad) 
|
Healthcare | |
Amgen Inc. (NASDAQ: AMGN) delivered a solid earnings report after the market closed on August 3. Shareholders hope the results will be enough to reverse the fortunes of AMGN stock, down 12% in 2023.
But heading into earnings, analyst sentiment suggests that all the growth may already be priced i... Read the Full Story |
|
From Our Partners | | A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.
This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | | Click here to learn this company's name for free today |
|
Industrials | |
Shares of XPO (NYSE: XPO) have been on a stratospheric rise since the first quarter of 2023, blowing past all expectations and delivering a massive 165% advance in less than six months.
Some market participants speculate that this rally has run out of steam, but you can't fight the trend.
Durin... Read the Full Story |
|
Consumer Discretionary | |
Starbucks Corporation (NASDAQ: SBUX) share prices are at a turning point, and a breakout is imminent. The market has been consolidating at the low end of a trading range following a minor correction, but that episode is over.
The likely scenario is that upward price pressure will continue to bui... Read the Full Story |
|
From Our Partners | | Looking for better stock ideas? Sign-up to receive The Early Bird Stock of the Day. Each day, MarketBeat's team of expert research analysts identifies one compelling stock and provides both a bull case and a bear case for each company. | | Get The Early Bird's Stock of the Day (Free) |
|
Energy | |
Natural gas is one of the world's most reliable energy sources due to its low prices and lower environmental impact, especially when compared with other nonrenewable energy sources like oil and coal.
It has become a key pillar of modern economies worldwide because it also serves as a cleaner a... Read the Full Story |
|
Industrials | |
We don’t know how much relief most Americans are feeling from the effects of inflation, particularly at the grocery store. But we live in a data-driven world, and the data says that inflation is retreating on a year-over-year basis.
Still, inflation is growing above the Federal Reserve&rsq... Read the Full Story |
|
From Our Partners | | Tim Sykes built a trading strategy for people who can't watch charts from 9:30 to 4:00 every day.
It's not a discipline problem, it's a schedule problem, and Sykes has spent years developing an approach that fits around a job, a family, and a real life.
Every claim is backed by verified profits, so see the results for yourself. | | Click here to see how the strategy works for busy people |
|
Consumer Staples | |
Like a soggy bowl of cereal, it’s been a forgettable summer for General Mills, Inc. (NYSE:GIS).
Since posting mixed second quarter financial results at the end of June, the packaged foods leader has seen its share price dip more than 7%. The defensive stock’s uncharacteristic downtre... Read the Full Story |
|
Consumer Discretionary | |
Kellogg Company's (NYSE: K) price action is mixed following the Q2 report, but details within the release suggest the company is a Buy going into its planned separation. The separation is slated to be completed in Q4 this year and will result in 2 publicly traded companies.
The 1st will be WK Kel... Read the Full Story |
|
Finance | |
The financial sector has steadily firmed over recent months, as the Financial Select Sector SPDR Fund (NYSE: XLF) has climbed over 11% in three months after finding support near a critical level. In the dynamic world of financials, two stocks have caught the attention of investors: JPMorgan Chase ... Read the Full Story |
|
Finance | |
Europe’s largest bank fell along with the broader global market on August 2, despite reporting strong year-over-year revenue and earnings growth the day before.
HSBC Holdings plc (NYSE: HSBC) reported a second-quarter profit of $1.70 a share, up 26% from the year-earlier quarter.
Revenue... Read the Full Story |
|
Technology | |
With AI spending on the rise by giants such as Alphabet Inc. (NASDAQ: GOOGL) and Microsoft Corp. (NASDAQ: MSFT), other chipmakers besides juggernaut Nvidia Corp. (NASDAQ: NVDA) are set to benefit.
One such company is Marvell Technology Inc. (NASDAQ: MRVL), which expects its AI chip revenue to do... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. | | View Today's Stock Pick |
|
